To confirm the therapeutic effect of CXCR2 inhibition, SB225002, a selective CXCR2 inhibitor, was used in bothorthotopic lung cancer model and subcutaneous tumor model (Fig. 5a). Here, CXCR2 is linked to lung cancer.